As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...
Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...
Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets. The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration ...
“We’re confident that U.S. surgeons will agree with what their Canadian colleagues have already told us: enVista Envy delivers exceptional outcomes and meets cataract patients’ high expectations, as ...
lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Read More on BLCO: Bausch + Lomb Corporation ...
Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...
It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback